Lexeo Therapeutics (LXEO): OrbiMed entities disclose combined 5% ownership stake

Rhea-AI Filing Summary

Lexeo Therapeutics, Inc. has been reported as held by funds affiliated with OrbiMed. OrbiMed Advisors LLC reports beneficial ownership of 3,203,050 shares of common stock, representing 4.1% of the class, with shared voting and dispositive power over these shares and no sole power. OrbiMed Capital LLC reports beneficial ownership of 744,800 shares, representing 1.0% of the class, with sole voting and dispositive power over these shares. In the aggregate, the reporting persons state they hold 5.0% of Lexeo’s common stock on behalf of other persons entitled to dividends or sale proceeds. Investment and voting power is exercised through a management committee of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the reported shares.

Key Figures

OrbiMed Advisors LLC shares: 3,203,050 shares OrbiMed Advisors LLC percent of class: 4.1% OrbiMed Capital LLC shares: 744,800 shares +3 more

6 metrics

OrbiMed Advisors LLC shares 3,203,050 shares Beneficially owned Lexeo common stock reported by OrbiMed Advisors LLC

OrbiMed Advisors LLC percent of class 4.1% Percent of Lexeo common stock class held by OrbiMed Advisors LLC

OrbiMed Capital LLC shares 744,800 shares Beneficially owned Lexeo common stock reported by OrbiMed Capital LLC

OrbiMed Capital LLC percent of class 1.0% Percent of Lexeo common stock class held by OrbiMed Capital LLC

Aggregate ownership 5.0% Combined Lexeo common stock held on behalf of other persons by the reporting entities

Par value per share $0.0001 per share Par value of Lexeo Therapeutics common stock

Key Terms

beneficial ownership, shared voting power, sole dispositive power, shared dispositive power, +1 more

5 terms

beneficial ownership financial

"Amount beneficially owned: OrbiMed Advisors LLC: 3,203,050 OrbiMed Capital LLC: 744,800"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

shared voting power financial

"Shared Voting Power 3,203,050.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

sole dispositive power financial

"Sole Dispositive Power 744,800.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

shared dispositive power financial

"Shared Dispositive Power 3,203,050.00"

Investment Company Act of 1940 regulatory

"investment company registered under the Investment Company Act of 1940"

A U.S. federal law that sets the rulebook for pooled investment vehicles such as mutual funds, exchange-traded funds and similar money managers, requiring them to register with regulators, disclose holdings and fees, limit conflicts of interest, and follow governance standards. It matters to investors because these protections and transparency rules act like a referee and scoreboard, helping people compare funds, trust that managers follow fair practices, and spot hidden costs or risks.

FAQ

How much of Lexeo Therapeutics (LXEO) does OrbiMed Advisors LLC report owning?

OrbiMed Advisors LLC reports 3,203,050 shares of Lexeo Therapeutics common stock, representing 4.1% of the outstanding class, with shared voting and dispositive power over all of these shares.

What stake in Lexeo Therapeutics (LXEO) is reported by OrbiMed Capital LLC?

OrbiMed Capital LLC reports beneficial ownership of 744,800 shares of Lexeo Therapeutics common stock, equal to 1.0% of the class, with sole voting and sole dispositive power over these shares.

What is the aggregate percentage of Lexeo Therapeutics (LXEO) shares held by the OrbiMed reporting entities?

The reporting persons state they hold an aggregate of 5.0% of Lexeo Therapeutics common stock on behalf of other persons who are entitled to dividends or sale proceeds from these shares.

Who controls voting and investment decisions for OrbiMed’s Lexeo Therapeutics (LXEO) holdings?

OrbiMed Advisors LLC and OrbiMed Capital LLC state that investment and voting power over Lexeo shares is exercised through a management committee of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu.

Do OrbiMed’s committee members claim personal beneficial ownership of Lexeo Therapeutics (LXEO) shares?

The filing states that committee members Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu each disclaim beneficial ownership of the Lexeo Therapeutics common shares reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 05:36 PM Accepted by SEC EDGAR 08/14/2026 - 05:36 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Lexeo Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

52886X107

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 52886X107

1

Names of Reporting Persons

OrbiMed Advisors LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,203,050.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,203,050.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,203,050.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.1 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP Number(s): 52886X107

1

Names of Reporting Persons

OrbiMed Capital LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 744,800.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 744,800.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

744,800.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

1.0 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Lexeo Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 345 Park Avenue South, Floor 6, New York, NY 10010
Item 2.
(a)	Name of person filing: OrbiMed Advisors LLC OrbiMed Capital LLC
(b)	Address or principal business office or, if none, residence: 601 Lexington Avenue, 54th Floor New York, NY 10022
(c)	Citizenship: Please refer to Item 4 on each cover sheet for each filing person.
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP Number(s): 52886X107
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: OrbiMed Advisors LLC: 3,203,050 OrbiMed Capital LLC: 744,800
(b)	Percent of class: OrbiMed Advisors LLC: 4.1% OrbiMed Capital LLC: 1.0%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: OrbiMed Advisors LLC: 0 OrbiMed Capital LLC: 744,800
	(ii) Shared power to vote or to direct the vote: OrbiMed Advisors LLC: 3,203,050 OrbiMed Capital LLC: 0
	(iii) Sole power to dispose or to direct the disposition of: OrbiMed Advisors LLC: 0 OrbiMed Capital LLC: 744,800
	(iv) Shared power to dispose or to direct the disposition of: OrbiMed Advisors LLC: 3,203,050 OrbiMed Capital LLC: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Reporting Persons hold 5.0% of the shares of Common Stock in the aggregate on behalf of other persons who have the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, such securities. OrbiMed Advisors LLC and OrbiMed Capital LLC exercise investment and voting power over the shares of Common Stock through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares of Common Stock reported herein.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

OrbiMed Advisors LLC

Signature:	/s/ Carl L. Gordon
Name/Title:	Carl L. Gordon / Member
Date:	08/14/2026

OrbiMed Capital LLC

Signature:	/s/ Carl L. Gordon
Name/Title:	Carl L. Gordon / Member
Date:	08/14/2026